Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine
about
Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancerTreating refractory leukemias in childhood, role of clofarabineNucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathwayOral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 studyPhase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.An Escherichia coli system expressing human deoxyribonucleoside salvage enzymes for evaluation of potential antiproliferative nucleoside analogs.A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndromeClofarabine in leukemia.Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity.The role of clofarabine in acute myeloid leukemia.Deconstructing nucleotide binding activity of the Mdm2 RING domain.The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodelingClofarabine: past, present, and future.Clofarabine: emerging role in leukemias.Clofarabine for the treatment of adult acute myeloid leukemia.The cladribine conundrum: deciphering the drug's mechanism of action.Clofarabine 5'-di and -triphosphates inhibit human ribonucleotide reductase by altering the quaternary structure of its large subunitInterstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy.Nucleoside transporters in chronic lymphocytic leukaemia.Emerging treatments in acute myeloid leukaemia.Biodistribution and PET imaging of [(18)F]-fluoroadenosine derivatives.A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemiasClofarabine targets the large subunit (α) of human ribonucleotide reductase in live cells by assembly into persistent hexamersClofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review.Pyrimidine and purine analogues, effects on cell cycle regulation and the role of cell cycle inhibitors to enhance their cytotoxicity.Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.Clofarabine in pediatric acute leukemia: current findings and issues.Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?Clofarabine in the treatment of myelodysplastic syndromes.Synthesis of 2'-deoxy-2'-[18F]fluoro-9-β-D-arabinofuranosylguanine: a novel agent for imaging T-cell activation with PET.A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine.2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia and chronic lymphocytic leukemia.Purine analogs in lymphoproliferative disorders.2-Chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies.In vitro evaluation of B-CLL cells apoptotic responses to irradiation.On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment.Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant.Clofarabine combinations as acute myeloid leukemia salvage therapy.
P2860
Q24642847-0BE240CD-2B29-4D7A-9B40-49A074568CDEQ24647279-DC7BFDAB-1232-418A-9D92-6CCA8330C5F8Q28378265-E5B834FF-F966-487D-9457-CDB17DF146A8Q33405103-C1BFA06C-610C-46D8-BD64-B5D0C201ACD9Q33412609-24119358-7FE0-471F-B4AF-3591BBD27354Q33699299-1AB21E03-C4A5-4AA9-87EA-E7B7DE36FA97Q33843955-8CDBEC4D-D0A0-4DD9-9C5C-A446BE3E5FF3Q34150263-A5ECAFA6-75C0-4A3D-98AA-8320A8A80D93Q34159634-963BCB1C-A6D0-4FB5-A140-DC0E9A1ACE5DQ34298181-DBADE9DD-EFFF-4676-91A9-94070F4C7C35Q34368142-CA9C8945-DABD-44E3-A227-FECF2BB5ACA7Q34425136-AD62FCAD-8D26-43A9-89CA-000855EE8C4AQ34686726-3AB66B7A-51ED-4B39-96AE-95294B839BC3Q35000135-204DE036-9F28-471B-A425-D0F2B522CCD7Q35009273-83BEA0B1-1E34-4EBD-941E-CB8FD8EF3BE3Q35016421-817D023C-7351-4CA3-AB47-CAD73F23EBD5Q35049193-1ABFFC2D-B899-4AF1-BEF3-7A22BEBF7DB4Q35136616-B137097C-74CA-4E05-BF59-1A7230F7F454Q35567292-5FB74C00-66E9-4719-B430-93CD7952F63DQ35635321-02ACE7D8-6710-49C5-ACA1-9FEDBA887ABBQ35779278-E8679CFB-3139-4C1E-A410-94282749E255Q35867482-16A6263F-1AC5-4358-B9BE-586185DDEAAAQ35990683-F1E2D3E1-FB13-41C9-9079-6AFB3488B0AFQ36075766-A209566D-429D-4157-82D3-B7A6513D2BE0Q36128479-12688639-4603-4C06-BE91-7580DF949BB5Q36326258-67256AC1-67AB-4E1A-91B5-8AD4099EE8ADQ36378036-1D617E14-FA95-446C-B4B1-6D953A1BF70BQ36915178-D57C9F31-ADD3-43AE-8BF8-BDCAB4295D37Q37987061-033EEDB9-1A00-402D-83C6-59D5729C3079Q37994256-B26E15F4-6453-44FD-9176-6F84FF4C97B2Q38177310-824450A7-7335-4CED-978E-9345ACBFC533Q39656230-39662062-5325-45E9-956E-5A1CCC1EF235Q39818678-9B134289-AFE8-40A2-BE3B-16918938A16DQ40621419-75186A3F-C312-4023-82E4-E6FFE1533F5AQ40621426-C7968A1A-1C2E-4CB6-8F34-0D9166F1EFE5Q40709682-AC90DC41-E4C6-44BB-BEC1-0F6340402CC9Q40811434-62A6BDE2-223D-404E-B04B-7CA933D5E506Q41049811-54F06742-CD04-458C-832A-3B1B1738AD88Q41715517-A14956E0-038C-4FB0-91DE-B657CA34818BQ42048738-FCD366A5-F9A2-469C-AFD7-F4EE8A2D8621
P2860
Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Oral antilymphocyte activity a ...... abino-fluoro-2'-deoxyadenosine
@en
type
label
Oral antilymphocyte activity a ...... abino-fluoro-2'-deoxyadenosine
@en
prefLabel
Oral antilymphocyte activity a ...... abino-fluoro-2'-deoxyadenosine
@en
P2093
P2860
P356
P1476
Oral antilymphocyte activity a ...... abino-fluoro-2'-deoxyadenosine
@en
P2093
C J Carrera
D A Carson
D B Wasson
H B Cottam
L M Esparza
P2860
P304
P356
10.1073/PNAS.89.7.2970
P407
P577
1992-04-01T00:00:00Z